Is Pharvaris (PHVS) A Bargain On Strong Phase 3 Data Or Already Fully Priced?

Pharvaris (NasdaqGS:PHVS) drew fresh investor attention after presenting late breaking Phase 3 CHAPTER 3 data, which showed its oral deucrictibant extended release tablet significantly reduced hereditary angioedema attack rates with favorable tolerability.

Against that clinical backdrop, Pharvaris has seen mixed momentum. The share price has fallen 1.4% over the last day and 3% over the past week, but it has risen 11.1% over 30 days and 26% year to date. The 1 year total shareholder return of 41.7% and 3 year total shareholder return above 100% point to investors rewarding the longer track record more than the latest pullback as the market digests fresh trial data and recent quarterly loss figures.

Compare Pharvaris with a curated group of rare disease and complex care peers by scanning the 36 healthcare AI stocks.

Pharvaris now trades well below the average analyst valuation range after a strong year to date run. Is the recent pullback enough to reset expectations closer to fair value, or is it still too early to tell?

Most Popular Narrative: 42% Undervalued

Against Pharvaris' last close at $33.36, the analyst consensus Narrative on Simply Wall St points to a fair value near $57.33, implying a sizeable valuation gap based on long range revenue and earnings forecasts built into that model.

Combined development of deucrictibant immediate release for on demand use and extended release for prophylaxis, backed by data supporting safe concurrent use, can position Pharvaris to capture both acute and chronic hereditary angioedema treatment spend and potentially support higher overall revenue per patient as physicians consolidate therapy around a single mechanism.

See why 2 investors see Pharvaris as 42% undervalued.

Result: Fair Value of $57.33 (UNDERVALUED)

Still, the Pharvaris story hinges on successful deucrictibant approvals and on funding ongoing losses without heavy dilution, both of which could challenge the current undervaluation thesis.

Find out about the key risks to this Pharvaris narrative.

Next Steps

Mixed messages around Pharvaris can easily sway sentiment, so consider acting promptly and work through the numbers yourself using the 2 key rewards and 2 important warning signs.

Looking for more ideas beyond Pharvaris?

Do not stop with Pharvaris if you want a fuller picture of what the market is offering right now.

• Target resilient cash generators by scanning a list of solid balance sheet and fundamentals (24 results) that focuses on companies pairing sturdy finances with grounded fundamentals.
• Hunt for potential mispricings using the 32 high quality undervalued stocks to spot businesses where quality metrics and current prices look out of sync.
• Zero in on early stage opportunities by reviewing the 13 elite penny stocks with strong financials that filter for stronger balance sheets and more robust financial profiles.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com